{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:30:45Z","timestamp":1786113045839,"version":"build-2736575974"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100021171","name":"Guangdong Basic and Applied Basic Research Foundation","doi-asserted-by":"crossref","award":["2022A1515140171"],"award-info":[{"award-number":["2022A1515140171"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,9]]},"abstract":"<jats:p>\n                    Treatment options for recurrent osteosarcoma remain limited, and prognosis is poor. Pazopanib, a multi-targeted tyrosine kinase inhibitor, has shown activity in various sarcomas. This study evaluated the efficacy and safety of pazopanib combined with doxorubicin and cisplatin (Paz\u2005+\u2005AP regimen) in patients with recurrent osteosarcoma and analyzed its impact on survival. This single-center retrospective cohort study included recurrent osteosarcoma patients treated between February 2022 and February 2023. Propensity score matching was used to balance baseline characteristics. A total of 100 patients were analyzed: 50 received the Paz\u2005+\u2005AP regimen, and 50 received conventional chemotherapy (AP regimen). Treatment efficacy was assessed using response evaluation criteria in solid tumors (RECIST 1.1) criteria. The primary endpoint was progression-free survival (PFS); secondary endpoints included overall survival (OS), objective response rate, disease control rate, safety, and treatment compliance. Baseline characteristics were well balanced between groups (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&gt;\u2005.05). The Paz\u2005+\u2005AP group achieved a higher disease control rate than the control group (62.0% vs 42.0%,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.046), whereas the difference in objective response rate was not significant (26.0% vs 14.0%,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.13). Median PFS was significantly longer in the Paz\u2005+\u2005AP group than in controls (5.1 vs 2.2 months,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.04). Although the median OS was slightly shorter in the Paz\u2005+\u2005AP group (8.0 vs 9.6 months), its survival curve declined more slowly after 12 months, showing a significant difference (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.03). The incidence of adverse events was comparable (92.0% vs 88.0%), though hypertension (28.0% vs 10.0%,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.03) and hand-foot syndrome (22.0% vs 4.0%,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.01) were more frequent with pazopanib. No differences were observed in grade \u22653 or serious adverse events. Subgroup analysis indicated greater PFS benefits among patients with lung metastasis, recurrence interval \u22656 months, Eastern Cooperative Oncology Group (ECOG 0\u20131), and those receiving full-dose pazopanib. The Paz\u2005+\u2005AP regimen significantly prolonged PFS and improved disease control in recurrent osteosarcoma, with manageable toxicity and good compliance. Although OS improvement was limited, the regimen showed potential clinical value, particularly for patients with favorable performance status and longer recurrence intervals. Prospective studies are warranted to confirm these findings.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000046576","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T20:01:54Z","timestamp":1767988914000},"page":"e46576","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Pazopanib combined with doxorubicin and cisplatin in recurrent osteosarcoma: A retrospective cohort study"],"prefix":"10.1097","volume":"105","author":[{"given":"Wei-Luo","family":"Cai","sequence":"first","affiliation":[{"name":"Department of Spine Surgery, The First Affiliated Hospital, Jinan University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mo","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Musculoskeletal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng-Wang","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Musculoskeletal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Shanghai Sixth People\u2019s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang-Jun","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Musculoskeletal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiong-Sheng","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Spine Surgery, The First Affiliated Hospital, Jinan University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gen-Long","family":"Jiao","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery\/Dongguan Key Laboratory of Central Nervous System Injury and Repair, The Sixth Affiliated Hospital of Jinan University, Dongguan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260805","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1002\/cncr.27414","article-title":"Outcome for adolescent and young adult patients with osteosarcoma: a report from the Children\u2019s Oncology Group.","volume":"118","author":"ReferenceJaneway","year":"2012","journal-title":"Cancer"},{"key":"R2-20260805","first-page":"343","article-title":"Osteosarcoma in adolescents and young adults: clinical characteristics and survival outcomes.","volume":"13","author":"Lee","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R3-20260805","first-page":"187","article-title":"Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 study.","volume":"20","author":"Smeland","year":"2019","journal-title":"Lancet Oncol"},{"key":"R4-20260805","doi-asserted-by":"crossref","first-page":"5044","DOI":"10.3390\/cancers15205044","article-title":"Osteosarcoma in pediatric and adult populations: a review of current therapeutic strategies and future directions.","volume":"15","author":"Kim","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R5-20260805","first-page":"e813","article-title":"Pazopanib in advanced soft tissue sarcomas: a review of the EORTC soft tissue and bone sarcoma group experience.","volume":"24","author":"Lee","year":"2019","journal-title":"Oncologist"},{"key":"R6-20260805","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1186\/s12885-019-5988-3","article-title":"Safety and efficacy of pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) retrospective subgroup analyses.","volume":"19","author":"Cesne","year":"2019","journal-title":"BMC Cancer"},{"key":"R7-20260805","first-page":"1758835924122345","article-title":"Pazopanib in the real-world setting in soft tissue sarcomas: an Italian tumor registry study.","volume":"16","author":"Vincenzi","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"R8-20260805","first-page":"1064","article-title":"Phase II study of pazopanib with oral topotecan in patients with recurrent sarcomas including soft tissue sarcomas.","volume":"39","author":"Schulte","year":"2021","journal-title":"Invest New Drugs"},{"key":"R9-20260805","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3390\/cancers14020360","article-title":"Metastatic progression of osteosarcomas: a review.","volume":"14","author":"Odri","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R10-20260805","first-page":"124ra27","article-title":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.","volume":"3","author":"Goel","year":"2011","journal-title":"Sci Transl Med"},{"key":"R11-20260805","first-page":"455","article-title":"Targeted antiangiogenic agents in combination with chemotherapy: a comprehensive review of preclinical and clinical experience.","volume":"9","author":"Vo","year":"2016","journal-title":"Cancer Prev Res (Phila)"},{"key":"R12-20260805","first-page":"175","article-title":"Pazopanib induced hand-foot syndrome: a case report and literature review.","volume":"9","author":"Sundriyal","year":"2015","journal-title":"J Med Case Rep"},{"key":"R13-20260805","first-page":"2401","article-title":"Management of cytotoxic chemotherapy-induced hand-foot syndrome: a critical review and practical guide.","volume":"28","author":"Kwakman","year":"2020","journal-title":"Support Care Cancer"},{"key":"R14-20260805","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1002\/cncr.29888","article-title":"Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of pazopanib in patients with metastatic soft tissue sarcoma.","volume":"122","author":"Beaumont","year":"2016","journal-title":"Cancer"},{"key":"R15-20260805","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1470-2045(19)30825-3","article-title":"Cabozantinib in advanced Ewing sarcomas and osteosarcomas: a multicentre, single-arm, phase 2 trial.","volume":"21","author":"Italiano","year":"2020","journal-title":"Lancet Oncol"},{"key":"R16-20260805","first-page":"823","article-title":"A phase I and pharmacokinetic trial of pazopanib in children with soft tissue sarcoma and other refractory solid tumors.","volume":"72","author":"Gaspar","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"R17-20260805","first-page":"3542","article-title":"Phase II trial of pazopanib in children and adolescents with refractory solid tumors: a Children\u2019s Oncology Group study.","volume":"39","author":"Wagner","year":"2021","journal-title":"J Clin Oncol"},{"key":"R18-20260805","first-page":"1449","article-title":"Safety and efficacy of pazopanib in advanced soft tissue sarcoma: PALETTE study final overall survival analysis.","volume":"28","author":"Gelderblom","year":"2017","journal-title":"Ann Oncol"},{"key":"R19-20260805","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S1470-2045(14)71136-2","article-title":"Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.","volume":"16","author":"Grignani","year":"2015","journal-title":"Lancet Oncol"},{"key":"R20-20260805","first-page":"5301","article-title":"Pazopanib as maintenance therapy after standard chemotherapy in patients with osteosarcoma: a pilot study.","volume":"40","author":"Uehara","year":"2020","journal-title":"Anticancer Res"},{"key":"R21-20260805","first-page":"16","article-title":"Safety and efficacy of pazopanib therapy in sarcoma patients with renal dysfunction.","volume":"3","author":"Mahmood","year":"2013","journal-title":"Clin Sarcoma Res"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000046576","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T17:02:07Z","timestamp":1785949327000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000046576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000046576","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]},"assertion":[{"value":"2025-09-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}